Skip to main content
PRME logo

PRME · Prime Medicine, Inc. · Documents

Track PRME — free
$3.84 +0.02 (+0.52%) At close · Nov 19
Market Cap
$698.58M
Shares
181.92M
Volume · Nov 19 3.99M Avg daily vol (3M) 4.59M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $4.63M up 55.3% 10-K filed Mar 3, 2026 Quarterly report FY2026 Q3 Revenue $4.21M up 243.9% 10-Q filed Nov 12, 2026 Latest results $143.7 million raise extends cash runway through 2027 8-K filed Nov 12, 2026
2026
Nov 16
Investor event
First approval targeted next year as clinical catalysts approach

Prime Medicine expects first approval next year for chronic granulomous disease; Wilson disease Phase 1-2 began dosing in October and targets 2027 data, while alpha-1 antitrypsin’s first patient dose is expected end of the year or soon after.

9 source passages
we're going towards our first approval next year. And for an ex vivo program, it's something called chronic granulomous disease. you dosed your first patient in your global phase 1-2 in October. We're guiding to data in 2027. And let's shift gears to alpha-1 antitrypsin. Yeah, so we'll announce first patient dose. And for this program, if you think about the IND, you know, cleared in September You look to about two to three months, give or take, for first patient dose. So I'd say we're kind of on pace. So, you know, you can expect something, you know, end of the year or soon after as to getting that first patient in if we hit our timelines. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Substantial doubt exists about continuing as a going concern

Prime Medicine, Inc. concluded substantial doubt exists about its ability to continue as a going concern for 12 months, reporting $61.2 million in cash, cash equivalents and short-term investments as of September 30, 2026, and $74.8 million including restricted cash.

Revenue $4.21M ▲ 243.9% Net loss $39.04M Diluted EPS -$0.22
Read from the MD&A section
2 source passages
As of September 30, 2026, we had cash, cash equivalents, and investments of $61.2 million, excluding our restricted cash, or $74.8 million, including restricted cash. As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued. Open the document at this passage
Nov 12
Current report 8-K
$143.7 million raise extends cash runway through 2027

Prime Medicine raised $143.7 million in gross proceeds, reporting pro-forma cash of approximately $209.5 million and a runway through 2027 after dosing the first patient with PM577a and receiving FDA clearance for PM647.

Financial results
5 source passages
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended September 30, 2026 and provided a business update. Closed underwritten public offering, including the full exercise of the underwriters’ option to purchase additional shares, raising $143.7 million in gross proceeds Pro-forma cash, cash equivalents, investments and restricted cash of approximately $209.5 million; cash runway through 2027 First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 Received FDA clearance of Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency; initial clinical data expected in 2027 Open the document at this passage
Nov 12
Current report 8-K Events of Nov 10
Offering Seeks $134.7 Million in Estimated Net Proceeds

Prime Medicine priced 35,714,286 shares at $3.50 per share and granted underwriters an option for 5,357,142 additional shares. Estimated net proceeds, including full option exercise and after underwriting discounts, commissions and offering expenses, are approximately $134.7 million.

Entered into a material agreement Read from the first part of this long document
3 source passages
On November 10, 2026, Prime Medicine, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering (the “Offering”) of 35,714,286 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.00001 per share (“Common Stock”), at a public offering price of $3.50 per share. In addition, the Company has granted the Underwriters an option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase, at the public offering price, less the underwriting discounts and commissions, up to an additional 5,357,142 shares of Common Stock (the “Option Shares” and together with the Underwritten Shares, the “Shares”). The Company estimates that the net proceeds from the Offering, including from the exercise in full of the Underwriters' option to purchase the Option Shares, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, will be approximately $134.7 million. Open the document at this passage
Nov 10
Current report 8-K
Cash and investments estimated at $61.2 million

Prime Medicine estimated cash, cash equivalents and short-term investments of approximately $61.2 million as of September 30, 2026, excluding approximately $13.7 million of restricted cash; the unaudited figures remained subject to quarter-end closing adjustments.

Financial results, Other events
Source passage
On November 10, 2026, Prime Medicine, Inc. (the “Company”) announced that the preliminary unaudited estimates of its cash, cash equivalents, and short-term investments were approximately $61.2 million as of September 30, 2026, excluding its restricted cash of approximately $13.7 million. Open the document at this passage
Jul 8
Current report 8-K Events of Jul 6
Other events AI summary on its way
Mar 3
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $4.63M ▲ 55.3% Net loss $201.14M Diluted EPS -$1.35
2025
Feb 28
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $2.98M Net loss $195.88M Diluted EPS -$1.65
2024
Showing 1–50 of 92 documents
Key facts CIK 1894562 CUSIP 74168J101 13F (30d) 194 filings 179 filers Visit website Investor relations